Phase 1 study of PI-2620 in patients with progressive supranuclear palsy
Latest Information Update: 28 Sep 2020
Price :
$35 *
At a glance
- Drugs PI 2620 (Primary)
- Indications Progressive supranuclear palsy
- Focus Diagnostic use
- 28 Sep 2020 New trial record